Purple Biotech Reports Positive Phase 2 Pancreatic Cancer Study Results
Ticker: PPBT · Form: 6-K · Filed: Jun 27, 2024 · CIK: 1614744
Sentiment: bullish
Topics: clinical-trial-results, oncology, drug-development
TL;DR
Purple Biotech's pancreatic cancer drug CM24 shows positive interim Phase 2 results, potentially a big win.
AI Summary
On June 27, 2024, Purple Biotech Ltd. announced additional positive interim results from its Phase 2 study of CM24 for pancreatic cancer. The study is a randomized trial evaluating CM24 in combination with atezolizumab and chemotherapy.
Why It Matters
Positive results in a Phase 2 study for pancreatic cancer, a notoriously difficult-to-treat disease, could significantly advance Purple Biotech's drug candidate CM24 towards later-stage trials and potential market approval.
Risk Assessment
Risk Level: medium — While positive, these are interim Phase 2 results for a difficult cancer, and further trials are needed to confirm efficacy and safety.
Key Players & Entities
- Purple Biotech Ltd. (company) — The company reporting the results.
- CM24 (drug) — The drug candidate being studied.
- June 27, 2024 (date) — Date of the press release and announcement.
- pancreatic cancer (disease) — The disease being targeted by the study.
- atezolizumab (drug) — Drug used in combination therapy with CM24.
FAQ
What specific additional positive interim results were reported for the Phase 2 pancreatic cancer study?
The filing states "additional positive interim results" but does not specify the exact nature or quantitative details of these results in the provided text.
What is the status of the Phase 2 study for CM24 in pancreatic cancer?
The study is a randomized Phase 2 trial evaluating CM24 in combination with atezolizumab and chemotherapy, and it has reached the interim results stage.
What is the primary purpose of the CM24 drug candidate?
The filing indicates CM24 is being studied for its potential in treating pancreatic cancer, in combination with other therapies.
When was this information publicly disclosed by Purple Biotech Ltd.?
The press release announcing these results was issued on June 27, 2024.
What other drugs are being used in combination with CM24 in this study?
CM24 is being studied in combination with atezolizumab and chemotherapy.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 20 · Accepted 2024-06-27 07:47:33
Filing Documents
- ea0208615-6k_purple.htm (6-K) — 14KB
- ea020861501ex99-1_purple.htm (EX-99.1) — 21KB
- ex99-1_001.jpg (GRAPHIC) — 23KB
- 0001213900-24-056328.txt ( ) — 68KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. June 27, 2024 PURPLE BIOTECH LTD. By: /s/ Lior Fhima Lior Fhima Chief Financial Officer 2